Pharmacielo Stock Current Valuation
| PCLO Stock | CAD 0.09 0.01 5.88% |
Valuation analysis of Pharmacielo helps investors to measure Pharmacielo's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. Enterprise Value is likely to climb to about 85.3 M in 2024, whereas Enterprise Value Over EBITDA is likely to drop (4.11) in 2024. Fundamental drivers impacting Pharmacielo's valuation include:
Price Book 9.4797 | Enterprise Value 34.5 M | Enterprise Value Ebitda (6.50) | Price Sales 8.9082 | Forward PE 5.963 |
Overvalued
Today
Please note that Pharmacielo's price fluctuation is out of control at this time. Calculation of the real value of Pharmacielo is based on 3 months time horizon. Increasing Pharmacielo's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Pharmacielo stock is determined by what a typical buyer is willing to pay for full or partial control of Pharmacielo. Since Pharmacielo is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Pharmacielo Stock. However, Pharmacielo's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.09 | Real 0.0864 | Hype 0.09 | Naive 0.0789 |
The intrinsic value of Pharmacielo's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Pharmacielo's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Pharmacielo helps investors to forecast how Pharmacielo stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Pharmacielo more accurately as focusing exclusively on Pharmacielo's fundamentals will not take into account other important factors: Pharmacielo Company Current Valuation Analysis
Pharmacielo's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Pharmacielo Current Valuation | 34.53 M |
Most of Pharmacielo's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Pharmacielo is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Pharmacielo Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for Pharmacielo is extremely important. It helps to project a fair market value of Pharmacielo Stock properly, considering its historical fundamentals such as Current Valuation. Since Pharmacielo's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Pharmacielo's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Pharmacielo's interrelated accounts and indicators.
Click cells to compare fundamentals
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Pharmacielo has a Current Valuation of 34.53 M. This is 99.76% lower than that of the Pharmaceuticals sector and 99.54% lower than that of the Health Care industry. The current valuation for all Canada stocks is 99.79% higher than that of the company.
Pharmacielo is regarded second in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Health Care industry is at this time estimated at about 112.91 Million. Pharmacielo totals roughly 34.53 Million in current valuation claiming about 31% of equities under Health Care industry.Pharmacielo Fundamentals
| Return On Equity | -30.13 | ||||
| Return On Asset | -0.2 | ||||
| Operating Margin | (2.12) % | ||||
| Current Valuation | 34.53 M | ||||
| Shares Outstanding | 169.74 M | ||||
| Shares Owned By Insiders | 8.43 % | ||||
| Shares Owned By Institutions | 4.58 % | ||||
| Number Of Shares Shorted | 28.63 K | ||||
| Price To Book | 9.48 X | ||||
| Price To Sales | 8.91 X | ||||
| Revenue | 1.54 M | ||||
| Gross Profit | (4.17 M) | ||||
| EBITDA | (7.56 M) | ||||
| Net Income | (16.3 M) | ||||
| Cash And Equivalents | 33.46 M | ||||
| Cash Per Share | 0.34 X | ||||
| Total Debt | 15.71 M | ||||
| Debt To Equity | 2.70 % | ||||
| Current Ratio | 7.36 X | ||||
| Book Value Per Share | (0.03) X | ||||
| Cash Flow From Operations | (5.15 M) | ||||
| Short Ratio | 0.11 X | ||||
| Earnings Per Share | (0.08) X | ||||
| Target Price | 2.5 | ||||
| Beta | 2.39 | ||||
| Market Capitalization | 14.43 M | ||||
| Total Asset | 22.29 M | ||||
| Retained Earnings | (198.71 M) | ||||
| Working Capital | (18.09 M) | ||||
| Net Asset | 22.29 M |
About Pharmacielo Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Pharmacielo's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pharmacielo using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pharmacielo based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Pharmacielo Stock Analysis
When running Pharmacielo's price analysis, check to measure Pharmacielo's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pharmacielo is operating at the current time. Most of Pharmacielo's value examination focuses on studying past and present price action to predict the probability of Pharmacielo's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pharmacielo's price. Additionally, you may evaluate how the addition of Pharmacielo to your portfolios can decrease your overall portfolio volatility.